Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07264660 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-07264660 | EXPERIMENTAL | Participants will receive a single dose of PF-07264660 via IV infusion |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo via IV infusion |
| Name | Type | Description |
|---|---|---|
| PF-07264660 | DRUG | PF-07264660 solution for injection (single use only) |
| Placebo | OTHER | Placebo solution for injection (single use only) |
Inclusion Criteria: 1. Healthy male and female participants aged 18 to 65 years. 2. Body mass index (BMI) of 19-27.9 kilogram per meter squared, inclusive, and a total body weight \>50 kilograms (110 pounds). 3. Participants who are willing and able to comply with all scheduled visits, treatment pl...
Top 20 of 26 competitors
PF-07264660 is an investigational small molecule drug being developed by Pfizer, Inc. for atopic dermatitis. It is in Phase 1 clinical development. The compound has been studied in a completed Phase 1 trial in healthy adult participants in China.
PF-07264660 is being developed for the treatment of atopic dermatitis. It is an investigational therapy and has not been approved for any indication. The only completed clinical trial of PF-07264660 enrolled healthy adult volunteers rather than patients with atopic dermatitis.
PF-07264660 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating PF-07264660 in atopic dermatitis.
PF-07264660 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The drug remains investigational and has not been approved by the FDA or any other regulatory agency for atopic dermatitis or any other indication.
PF-07264660 has been evaluated in one completed Phase 1 trial, NCT06712082, titled A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants. The trial enrolled 12 healthy adult participants in China and was randomized, double-blind, and placebo-controlled.